What's Happening?
Curatis Holding AG and Neupharma Co., Ltd. have entered into an exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema (PTBE) in Japan. This agreement grants Neupharma the rights to develop and commercialize
corticorelin, a drug that has shown potential in reducing steroid use in PTBE patients, thereby minimizing severe side effects associated with glucocorticoids. The agreement includes upfront and milestone payments totaling up to CHF 83.5 million, along with royalties on sales. The drug is currently not approved for therapeutic use in the U.S. or elsewhere, but it has demonstrated efficacy in preclinical studies. Neupharma plans to conduct a pivotal clinical trial in Japan, with a meeting scheduled with the Japanese drug regulatory authority in summer 2026, and the study expected to start in 2027.
Why It's Important?
The agreement between Curatis and Neupharma is significant as it addresses a critical need for targeted therapies in treating PTBE, a condition associated with brain tumors that currently lacks approved treatments. The potential to reduce or replace steroid use with corticorelin could improve the quality of life for patients by avoiding severe side effects. The global market potential for corticorelin is estimated to exceed USD 1 billion annually, highlighting the economic impact of this development. Additionally, the collaboration underscores the importance of international partnerships in advancing medical treatments and expanding market reach.
What's Next?
Neupharma will proceed with the clinical trial process in Japan, aiming for regulatory approval. The outcome of these trials will be crucial in determining the drug's future in the Japanese market. Concurrently, Curatis is preparing for a pivotal Phase 3 study for approval in the U.S. and Europe, indicating a broader strategy to introduce corticorelin globally. The success of these trials could lead to significant advancements in PTBE treatment and potentially open new markets for Curatis and Neupharma.
